Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Karakterisering av ekstracellulære vesikler hos brystkreftpasienter

2. november 2026 oppdatert av: Fabio Corsi, Istituti Clinici Scientifici Maugeri SpA

Karakterisering av ekstracellulære vesikler i brystkreftpasienters plasma ved Single Molecule Detection Array (SiMoA) Digital ELISA

Extracellular vesicles (EVs) are lipid bilayer-delimited particles, naturally released from cells and mediators of intercellular cross-talk. In breast cancer (BC), EVs seem to be involved in the tumor microenvironment's shaping, in cancer cells invasion and in the set-up of metastasis.

Clinical studies have provided initial evidence that these vesicles may have a prognostic and predictive value in breast cancer. Considering their ubiquitous presence in body fluids and their minimally invasive assessment through blood sampling, EVs could have a potential as liquid biopsy-derived biomarkers. Their quantification though is a complex task requiring complicated and time-consuming pre-analytical procedures of EVs isolation.

This protocol want to develop a new method for the detection of tumor-derived-EVs associated proteins, based on the use of Single Molecule Array (SiMoA), a digital ELISA technology able to detect and quantify extremely low concentrations of target proteins or particles.

The aim of this study is to evaluate how this new technology can allow the quantification of EVs plasma levels in patients affected by BC, providing useful diagnostic and prognostic information.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a prospective, observational, monocentric and no profit study. The study involves the analysis of plasma from patients with breast cancer in order to quantify and characterize tumor-derived EVs at specific disease stages.

The enrollment of consecutive patients affected by BC referring to an EUSOMA-accredited Breast Unit is planned.

The patients will be divided into three pre-planned groups, as follows:

Population 1: patients diagnosed with early breast cancer patients (stage I-III) with indication to curative surgery.

Population 2: a control group made of sex- and age-matched healthy volunteers, not affected by cancer or chronic diseases.

Population 3: patients with metastatic breast cancer diagnosis. For each patient a blood sample will be collected and plasma will be isolated. A new SiMoA assay based on the use of anti-CD63 and anti-CD9 antibodies, two well known protein markers of EVs, will be used to capture and quantify EVs directly from plasma without requiring any prior sample processing.

The study will be conducted following the International Conference on Harmonization [ICH] Good Clinical Practice [GCP] guidelines. The Ethical Committee of ICS Maugeri authorized the study as protocol 2490/2020.

Studietype

Observasjonsmessig

Registrering (Antatt)

105

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Lombardy
      • Pavia, Lombardy, Italia, 27100

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Breast cancer patients

Beskrivelse

Inclusion Criteria:

  • Signing of a specific informed consent for participation to the study
  • Female sex

Population 1:

  • Diagnosis of early breast cancer;
  • Indication for surgery after multidisciplinary discussion.

Population 2:

- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.

Population 3:

  • Diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;
  • Indication to chemotherapy.

Exclusion Criteria:

Population 1:

  • Presence of distant metastases
  • Synchronous presence of a different tumor
  • Indication to neoadjuvant chemotherapy

Population 2:

  • Diagnosis of breast cancer
  • Synchronous presence of a different tumor or chronic disease

Population 3:

- Patients who are unfit for systemic chemotherapy treatment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Early Breast Cancer patients
  • Diagnosis of early breast cancer;
  • Indication for surgery after multidisciplinary discussion.

Analysis of plasma in order to quantify and characterize EVs

Metastatic Breast Cancer patients
  • First diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;
  • Indication to chemotherapy.

Analysis of plasma in order to quantify and characterize EVs

Healthy patients

- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.

Analysis of plasma in order to quantify and characterize EVs

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
EVs levels in early BC
Tidsramme: 36 months

Determination of plasma EVs levels in patients with EBC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls

36 months
EVs levels in metastatic BC
Tidsramme: 36 months

Determination of plasma EVs levels in patients with first diagnosis of metastatic BC by SIMOA digital ELISA and evaluation of the difference of their concentration compared to healthy controls

36 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
EVs levels after surgery
Tidsramme: 36 months

Determination of plasma EVs levels in patients with early BC one month after surgery and comparison with pre-surgery EVs levels in order to evaluate any qualitative of quantitative modifications in circulating EVs

36 months
EVs levels after chemotherapy treatment
Tidsramme: 36 months

Determination of plasma EVs levels in patients with first diagnosis of metastatic BC after 4 months of systemic therapy and comparison with pre-therapy EV's plasma levels

36 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2020

Primær fullføring (Faktiske)

30. september 2023

Studiet fullført (Antatt)

30. september 2027

Datoer for studieregistrering

Først innsendt

21. mars 2023

Først innsendt som oppfylte QC-kriteriene

3. april 2023

Først lagt ut (Faktiske)

4. april 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2490

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .